PT  - JOURNAL ARTICLE
AU  - John Busby
AU  - Cecile T J Holweg
AU  - Akiko Chai
AU  - Peter Bradding
AU  - Fang Cai
AU  - Rekha Chaudhuri
AU  - Adel H Mansur
AU  - James Laurence Lordan
AU  - John G Matthews
AU  - Andrew Menzies-Gow
AU  - Robert Niven
AU  - Tracy Staton
AU  - Liam G Heaney
TI  - Change in type-2 biomarkers and related cytokines with prednisolone in uncontrolled severe oral corticosteroid dependent asthmatics: an interventional open-label study
AID  - 10.1136/thoraxjnl-2018-212709
DP  - 2019 Aug 01
TA  - Thorax
PG  - 806--809
VI  - 74
IP  - 8
4099  - http://thorax.bmj.com/content/74/8/806.short
4100  - http://thorax.bmj.com/content/74/8/806.full
SO  - Thorax2019 Aug 01; 74
AB  - Type-2 biomarkers and related cytokines (IL-5, IL-13), lung function and asthma symptoms were measured in 44 poorly-controlled severe oral corticosteroid (OCS)-dependent asthmatics for up to 88 days after a 7-day prednisolone boost (0.5 mg/kg). High-dose OCS reduced median blood eosinophils (−60 cells/µl; 95% CI −140 to 10), periostin (−8.4 ng/mL; −11.6 to –2.8), FeNO (−19.0 ppb; −28.5 to –4.0), IL-5 (−0.17 pg/mL; −0.28 to –0.08) and IL-13 (−0.15 pg/mL; −0.27 to –0.03). There were small improvements in mean FEV1 (0.16 L; 0.05 to 0.27) and (Asthma Control Questionnaire) ACQ-7 score (0.3; 0.0 to 0.7). Study measures returned to baseline 1-month postintervention. Following rescue OCS, 1 month is sufficient before using type-2 biomarkers to guide long-term treatment.Trial registration number NCT01948401.